NRIX
- Nurix Therapeutics, Inc.
()
Overview
Company Summary
Nurix Therapeutics, Inc. is a biopharmaceutical company that operates in the field of targeted protein degradation (TPD). TPD is a novel approach to drug discovery and development that seeks to address diseases by selectively eliminating disease-causing proteins within cells. Nurix specializes in harnessing the body's natural protein regulation and degradation pathways to develop small molecule therapeutics.
The company's core expertise lies in the design and optimization of small molecules that can bind to specific proteins and tag them for degradation by the cell's ubiquitin-proteasome system. By controlling protein levels and eliminating disease-causing proteins, Nurix aims to modulate cellular processes and treat a wide range of diseases, including cancer, immune disorders, and neurodegenerative diseases.
Nurix leverages its proprietary drug discovery platform, DELigase, to rapidly identify and optimize small molecules with the ability to bind to target proteins of interest. DELigase integrates DNA-encoded libraries with a unique protein degradation assay to identify compounds that can effectively induce protein degradation while maintaining selectivity and safety.
The company collaborates with pharmaceutical partners to develop novel therapies based on its TPD platform, as well as advancing its internal pipeline of drug candidates. Nurix's goal is to generate innovative treatments that have the potential to transform patient outcomes and address unmet medical needs.
Overall, Nurix Therapeutics is revolutionizing the field of drug development through targeted protein degradation, with the aim of treating a variety of diseases by selectively eliminating disease-causing proteins within cells.